Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cardiovascular disease in women with breast cancer - a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Are cancer patients better off if they participate in clinical trials? A mixed methods study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Thyroid function in COVID-19 and the association with cytokine levels and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cohort profile: The COPENHAGEN Minipuberty Study-A longitudinal prospective cohort of healthy full-term infants and their parents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Variant PNLDC1, Defective piRNA Processing, and Azoospermia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Elevated serum levels of luteinizing hormone and slightly decreased serum levels of testosterone (mild Leydig cell insufficiency) is a common hormonal disturbance in testicular cancer (TC) survivors. A number of studies have shown that low serum levels of testosterone is associated with low grade inflammation and increased risk of metabolic syndrome. However, so far, no studies have evaluated whether testosterone substitution improves metabolic dysfunction in TC survivors with mild Leydig cell insufficiency.

METHODS/DESIGN: This is a single-center, randomized, double-blind, placebo-controlled study, designed to evaluate the effect of testosterone replacement therapy in TC survivors with mild Leydig cell insufficiency. Seventy subjects will be randomized to receive either testosterone replacement therapy or placebo. The subjects will be invited for an information meeting where informed consent will be obtained. Afterwards, a 52-weeks treatment period begins in which study participants will receive a daily dose of transdermal testosterone or placebo. Dose adjustment will be made three times during the initial 8 weeks of the study to a maximal daily dose of 40 mg of testosterone in the intervention arm. Evaluation of primary and secondary endpoints will be performed at baseline, 26 weeks post-randomization, at the end of treatment (52 weeks) and 3 months after completion of treatment (week 64).

DISCUSSION: This study is the first to investigate the effect of testosterone substitution in testicular cancer survivors with mild Leydig cell insufficiency. If positive, it may change the clinical handling of testicular cancer survivors with borderline low levels of testosterone.

TRIAL REGISTRATION: ClinicalTrials.gov : NCT02991209 (November 25, 2016).

OriginalsprogEngelsk
TidsskriftB M C Cancer
Vol/bind17
Udgave nummer1
Sider (fra-til)e461
ISSN1471-2407
DOI
StatusUdgivet - 3 jul. 2017

ID: 50677327